BG
BEAM icon

Bellevue Group’s Beam Therapeutics BEAM Stock Holding History

Bellevue Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111,510
Closed -$3.09M – 161
2025
Q4 		$3.09M Sell
111,510
-2,777,778
-96% -$70.9M 0.06% 86
2025
Q3 		$70.1M Hold
2,889,288
– – 1.46% 19
2025
Q2 		$49.1M Buy
2,889,288
+493,358
+21% +$8.59M 1.08% 22
2025
Q1 		$46.8M Buy
2,395,930
+877,809
+58% +$23M 1.05% 24
2024
Q4 		$37.6M Hold
1,518,121
– – 0.72% 30
2024
Q3 		$37.2M Buy
1,518,121
+100,000
+7% +$2.58M 0.6% 48
2024
Q2 		$33.2M Buy
1,418,121
+225,000
+19% +$5.53M 0.54% 54
2024
Q1 		$39.4M Buy
1,193,121
+498,300
+72% +$15.5M 0.6% 55
2023
Q4 		$18.9M Hold
694,821
– – 0.29% 76
2023
Q3 		$16.7M Sell
694,821
-600
-0.1% -$16.1K 0.27% 76
2023
Q2 		$22.2M Hold
695,421
– – 0.32% 71
2023
Q1 		$21.3M Sell
695,421
-1,300
-0.2% -$51.3K 0.31% 78
2022
Q4 		$27.2M Buy
696,721
+125,000
+22% +$5.6M 0.36% 73
2022
Q3 		$27.2M Sell
571,721
-900
-0.2% -$51.3K 0.39% 69
2022
Q2 		$22.2M Sell
572,621
-10,200
-2% -$405K 0.31% 82
2022
Q1 		$33.4M Sell
582,821
-30,000
-5% -$1.97M 0.39% 78
2021
Q4 		$48.8M Hold
612,821
– – 0.5% 66
2021
Q3 		$53.3M Hold
612,821
– – 0.54% 59
2021
Q2 		$78.9M Buy
612,821
+46,000
+8% +$3.67M 0.77% 42
2021
Q1 		$45.4M Buy
566,821
+170,000
+43% +$16.2M 0.48% 68
2020
Q4 		$32.4M Buy
+396,821
New +$19.5M 0.37% 76

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Bellevue Group's BEAM Position: Q1 2026 in Review

Bellevue Group sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 111,510 shares — an estimated $3.09M sold.

Bellevue Group first reported a position in BEAM in Q4 2020 and held it in 21 quarters. The position peaked at $78.9M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Bellevue Group reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 111,510 Beam Therapeutics shares in Q1 2026, an estimated $3.09M.
  • Bellevue Group first reported a position in Beam Therapeutics in Q4 2020 and held it in 21 quarters.
  • Bellevue Group's Beam Therapeutics position peaked at $78.9M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.